Provided by Tiger Fintech (Singapore) Pte. Ltd.

Genenta Science S.p.A.

4.25
+0.07721.85%
Post-market: 4.250.00000.00%16:00 EDT
Volume:3.09K
Turnover:12.99K
Market Cap:77.73M
PE:-8.42
High:4.25
Open:4.17
Low:4.17
Close:4.17
Loading ...

Company Profile

Company Name:
Genenta Science S.p.A.
Exchange:
NASDAQ
Establishment Date:
2014
Employees:
13
Office Location:
Via Olgettina No. 58,Milan,Milan,Italy
Zip Code:
20132
Fax:
- -
Introduction:
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.

Directors

Name
Position
Pierluigi Paracchi
Chief Executive Officer, Vice Chairman of the Board and General Manager
Stephen Squinto
Chairman of the Board
Anthony Marucci
Director
Daniela Bellomo
Director
Guido Guidi
Director
Luca Guidotti
Director
Roger Abravanel
Director

Shareholders

Name
Position
Pierluigi Paracchi
Chief Executive Officer, Vice Chairman of the Board and General Manager
Richard B. Slansky
Chief Financial Officer
Carlo Russo
Chief Medical Officer, Head of Development
Stefania Mazzoleni
Scientific Project Manager and Communications Officer